Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections

Bibliography

• Ambler RP. The structure of β-lactamases. Philos Trans R Soc Lond B Biol Sci 1980;289:321–31
   PubMed Web of Science ®Google Scholar
• Bush K, Jacoby GA. Updated functional classification of β-lactamases. Antimicrob Agents Chemother 2010;54:969–76
   PubMed Web of Science ®Google Scholar
• Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211–33
   PubMed Web of Science ®Google Scholar
• Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657–86
   PubMed Web of Science ®Google Scholar
• Falagas ME, Karageorgopoulos DE. Extended-spectrum β-lactamase-producing organisms. J Hosp Infect 2009;73:345–54
   PubMed Web of Science ®Google Scholar
• Jacoby GA. AmpC β-lactamases. Clin Microbiol Rev 2009;22:161–82
   PubMed Web of Science ®Google Scholar
• Rolain JM, Cornaglia G. Carbapenemases in Enterobacteriaceae: the magnitude of a worldwide concern. Clin Microbiol Infect 2014;20:819–20
   PubMed Web of Science ®Google Scholar
• Perez F, van Duin D. Carbapenem-resistant Enterobacteriaceae: A menace to our most vulnerable patients. Cleve Clin J Med 2013;80:224–33
   Google Scholar
• Dortet L, Poirel L, Nordmann P. Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria. BioMed Res Int 2014;2014:249856
   PubMed Web of Science ®Google Scholar
• Strateva T, Yordanov D. Pseudomonas aeruginosa – a phenomenon of bacterial resistance. J Med Microbiol 2009;58:1133–48
   PubMed Web of Science ®Google Scholar
• Maragakis LL, Perl TM. Acinetobacter baumannii: Epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008;46:1254–63
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010;50:133–64
   PubMed Web of Science ®Google Scholar
• Chen YH, Hsueh PR. Changing bacteriology of abdominal and surgical sepsis. Curr Opin Infect Dis 2012;25:590–5
   PubMed Web of Science ®Google Scholar
• Morrissey I, Hackel M, Badal R, et al. A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals 2013;6:1335–46
   Google Scholar
• Hoban DJ, Badal R, Bouchillon S, et al. In vitro susceptibility and distribution of β-lactamases in Enterobacteriaceae causing intra-abdominal infections in North America 2010-2011. Diagn Microbiol Infect Dis 2014;79:367–72
   PubMed Web of Science ®Google Scholar
• Babinchak T, Badal R, Hoban D, et al. Trends in susceptibility of selected gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005-2010. Diagn Microbiol Infect Dis 2013;76:379–81
   PubMed Web of Science ®Google Scholar
• Lagacé-Wiens PRS, Adam HJ, Low DE, et al. Trends in antibiotic resistance over time among pathogens from Canadian hospitals: results of the CANWARD study 2007–11. J Antimicrob Chemother 2013;68(Suppl 1):i23–9
   PubMed Web of Science ®Google Scholar
• Flamm RK, Farrell DJ, Sader HS, et al. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012). J Antimicrob Chemother 2014;69:1589–98
   PubMed Web of Science ®Google Scholar
• Montravers P, Gauzit R, Muller C, et al. Emergence of antibiotic-resistance bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996;23:486–94
   PubMed Web of Science ®Google Scholar
• Mosdell DM, Morris DM, Voltura A, et al. Antibiotic treatment for surgical peritonitis. Ann Surg 1991;214:543–9
   PubMed Web of Science ®Google Scholar
• Mazzulli T. Diagnosis and management of simple and complicated urinary tract infections (UTIs). Can J Urol 2012;19(Suppl 1):42–8
   PubMed Web of Science ®Google Scholar
• Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2010;50:625–63
   PubMed Web of Science ®Google Scholar
• Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013;34:1–14
   PubMed Web of Science ®Google Scholar
• Sader HS, Flamm RK, Jones RN. Frequency of occurrence and antimicrobial susceptibility of Gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009-2011). J Chemother 2014;26:133–8
   PubMed Web of Science ®Google Scholar
• Bouchillon S, Hoban DJ, Badal R, et al. Fluoroquinolone resistance among Gram-negative urinary tract pathogens: global SMART program results, 2009-2010. Open Microbiol J 2012;6:74–8
   PubMedGoogle Scholar
• Esparcia A, Artero A, Eiros JM, et al. Influence of inadequate antimicrobial therapy on prognosis in elderly patients with severe urinary tract infections. Eur J Intern Med 2014;25:523–7
   PubMed Web of Science ®Google Scholar
• MacVane SH, Tuttle LO, Nicolau DP. Impact of extended-spectrum β-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infections. J Hosp Med 2014;9:232–8
   PubMed Web of Science ®Google Scholar
• MacVane SH, Tuttle LO, Nicolau DP. Demography and burden of care associated with patients readmitted for urinary tract infection. J Microbiol Immunol Infect 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: No ESKAPE! an update from the infectious diseases society of america. Clin Infect Dis 2009;48:1–12
   PubMed Web of Science ®Google Scholar
• Appelbaum PC. 2012 and beyond: potential for the start of a second pre-antibiotic era? J Antimicrob Chemother 2012;67:2062–8
   PubMed Web of Science ®Google Scholar
• Hong M-C, Hsu DI, Bounthavong M. Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination. Infect Drug Res 2013;6:215–23
   PubMedGoogle Scholar
• Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 2013;68:2286–90
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S. Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenems-resistant Enterobacteriaceae. J Antimicrob Chemother 2013;68:1825–31
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M, et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011;55:390–4
   PubMed Web of Science ®Google Scholar
• Sader HS, Farrell DJ, Flamm RK, et al. Antimicrobial susceptibility of Gram-negative organisms isolates from patients hospitalized with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents 2014;43:328–34
   PubMed Web of Science ®Google Scholar
• Ehmann DE, Jahić H, Ross PL, et al. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci USA 2012;109:11663–8
   PubMed Web of Science ®Google Scholar
• Ehmann DE, Jahić H, Ross PL, et al. Kinetics of avibactam inhibition against Class A, C, and D β-lactamases. J Biol Chem 2013;288:27960–71
   PubMed Web of Science ®Google Scholar
• Lagacé-Wiens PRS, Tailor F, Simner P, et al. Activity of NXL 104 in combination with β-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing Class A extended-spectrum β-lactamases and Class C β-lactamases. Antimicrob Agents Chemother 2011;55:2434–7
   PubMed Web of Science ®Google Scholar
• Levasseur P, Girard A-M, Claudon M, et al. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2012;56:1606–8
   PubMed Web of Science ®Google Scholar
• Berkhout J, Melchers MJ, van Mil AC, et al. In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays. Antimicrob Agents Chemother 2015;59:1138–44
   PubMed Web of Science ®Google Scholar
• Sader HS, Castanheira M, Flamm RK, et al. Antimicrobial activity of ceftazidime-avibactam against gram-negative organisms collected from US medical centers in 2012. Antimicrob Agents Chemother 2014;58:1684–92
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang F, Zhao C, et al. In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother 2014;58:1774–8
   PubMed Web of Science ®Google Scholar
• Aktas Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL 104) in combination with β-lactams against gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2012;39:86–9
   PubMed Web of Science ®Google Scholar
• Flamm RK, Stone GG, Sader HS, et al. Avibactam reverts the ceftazidime MIC90 of European gram-negative bacterial clinical isolates to the epidemiological cut-off value. J Chemother 2014;26:333–8
   PubMed Web of Science ®Google Scholar
• Keepers TR, Gomez M, Celeri C, et al. Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2014;58:5297–305
   PubMed Web of Science ®Google Scholar
• Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infect Dis Clin N Am 2003;17:479–501
   PubMed Web of Science ®Google Scholar
• Muller AE, Punt N, Mouton JW. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother 2013;68:900–6
   PubMed Web of Science ®Google Scholar
• MacVane SH, Kuti JL, Nicolau DP. Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2014;58:1359–64
   PubMed Web of Science ®Google Scholar
• Coleman K, Levasseur P, Girard AM, et al. Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrob Agents Chemother 2014;58:3366–72
   PubMed Web of Science ®Google Scholar
• Nichols W, Levasseur P, Li J, et al. A threshold concentration of avibactam (AVI) during the pharmacokinetic decline phase, below which β-lactamase inhibition in Enterobacteriaceae becomes ineffective. [abstract A-1760]. Paper presented at 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 9-12 September, 2012; San Francisco, California, USA
   Google Scholar
• Berkhout J, Melchers MJ, Van Mill CH, et al. Pharmacodynamics of ceftazidime and avibactam in a neutropenic mouse lung model. [abstract A-1022]. Paper presented at 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 10-13 September, 2013; Denver, Colorado, USA
   Google Scholar
• Berkhout J, Melchers MJ, Van Mill CH, et al. Exposure response relationship of ceftazidime and avibactam in a neutropenic thigh model. [abstract A-1023]. Paper presented at 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 10-13 September, 2013; Denver, Colorado, USA
   Google Scholar
• Li J, Knebel W, Riggs M, et al. Population pharmacokinetic modeling of ceftazidime (CAZ) and avibactam (AVI) in healthy volunteers and patients with complicated intra-abdominal infection (cIAIs). [abstract A-634]. Paper presented at 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 9-12 September, 2012; San Francisco, California, USA
   Google Scholar
• Edeki T, Armstrong J, Li J. Pharmacokinetics of avibactam (AVI) and ceftazidime (CAZ) following separate or combined administration in healthy volunteers. [abstract A-1019]. Paper presented at 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 10-13 September, 2013; Denver, Colorado, USA
   Google Scholar
• Merdjan H, Tarral A, Haazen W, et al. Pharmacokinetics and tolerability of NXL 104 in normal subjects and patients with varying degrees of renal insufficiency [abstract P1598]. Paper presented at 20th European Congress of Clinical Microbiology and Infectious Diseases; 10-13 April, 2010; Vienna, Austria
   Google Scholar
• Li J, Zhou D, Nichols W, et al. Evaluation of ceftazidime-avibactam (CAZ-AVI) dose regimens for phase III study in patients with different renal function. [abstract A-635]. Paper presented at 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 9-12 September, 2012; San Francisco, California, USA
   Google Scholar
• FORTAZ®. Prescribing Information for Ceftazidime injection. GlaxoSmithKline, LLC; Research Triangle Park, NC: 2010
   Google Scholar
• Merdjan H, Rangaraju M, Tarral A. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Clin Drug Invest 2015;35:307–17
   PubMed Web of Science ®Google Scholar
• Endimiani A, Hujer KM, Hujer AM, et al. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2011;55:82–5
   PubMed Web of Science ®Google Scholar
• Levasseur P, Girard A-M, Lavallade L, et al. Efficacy of a ceftazidime-avibactam combination in a murine model of septicemia caused by Enterobacteriaceae species producing AmpC or extended-spectrum β-lactamases. Antimicrob Agents Chemother 2014;58:6490–5
   PubMed Web of Science ®Google Scholar
• Crandon JL, Schuck VJ, Banevicius MA, et al. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2012;56:6137–46
   PubMed Web of Science ®Google Scholar
• MacVane SH, Crandon JL, Nichols WW, et al. In vivo efficacy of humanized exposures of ceftazidime-avibactam in comparison with ceftazidime against contemporary Enterobacteriaceae isolates. Antimicrob Agents Chemother 2014;58:6913–19
   PubMed Web of Science ®Google Scholar
• Housman ST, Crandon JL, Nichols WW, et al. Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model. Antimicrob Agents Chemother 2014;58:1365–71
   PubMed Web of Science ®Google Scholar
• Dallow J, Otterson LG, Huband MD, et al. Microbiological interaction studies between ceftazidime-avibactam and lung surfactant and between ceftazidime-avibactam and antibacterial agents of other classes. Int J Antimicrob Agents 2014;44:552–6
   PubMed Web of Science ®Google Scholar
• Lucasti C, Popescu I, Ramesh MK, et al. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother 2013;68:1183–92
   PubMed Web of Science ®Google Scholar
• Vazquez JA, González Patzán LD, Stricklin D, et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 2012;28:1921–31
   PubMed Web of Science ®Google Scholar
• Mazuski JE, Gasnik L, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection – results from a Phase III program [abstract 0191]. Paper presented at 25th European Congress of Clinical Microbiology and Infectious Diseases; 25-28 April, 2015; Copenhagen, Denmark
   Google Scholar
• Carmeli Y, Armstrong J, Laud P, et al. Efficacy and safety of ceftazidime-avibactam and best available therapy in the treatment of ceftazidime-resistant infections – results from a Phase III study [abstract LBEV0061b]. Paper presented at 25th European Congress of Clinical Microbiology and Infectious Diseases; 25-28 April, 2015; Copenhagen, Denmark
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement. M100- S20 Wayne; PA, USA: 2010
   Google Scholar